Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1989-9-14
|
pubmed:abstractText |
In previous studies, we have found Hemate P (Behring) to be the only commercial virus-inactivated high-purity factor VIII concentrate that contains native von Willebrand factor. In the present study, Hemate P was given to 7 patients with the severe recessive form of von Willebrand's disease, to 2 patients with type Ia, to 1 patient with type IIB, and to 1 patient with type IIC von Willebrand's disease. A correction of the hemostatic defect was seen in all patients. Satisfactory hemostasis was also obtained in clinical situations, 1 patient undergoing major surgery and another being delivered, both without undue loss of blood. We conclude that Hemate P is an efficacious and safe product for use in cases of von Willebrand's disease when pharmacological correction of the hemostatic defect is not possible.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0042-9007
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
212-7
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading | |
pubmed:year |
1989
|
pubmed:articleTitle |
Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease.
|
pubmed:affiliation |
Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Sweden.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|